SAB Biotherapeutics (SABSW) Operating Margin (2021 - 2025)
SAB Biotherapeutics' Operating Margin history spans 5 years, with the latest figure at 24849.88% for Q4 2025.
- For Q4 2025, Operating Margin rose 3357614.0% year-over-year to 24849.88%; the TTM value through Dec 2025 reached 20340.96%, up 2358583.0%, while the annual FY2024 figure was 3244.87%, 154432.0% down from the prior year.
- Operating Margin reached 24849.88% in Q4 2025 per SABSW's latest filing, down from 29287.09% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 29287.09% in Q3 2025 to a low of 8726.26% in Q4 2024.
- Average Operating Margin over 5 years is 2875.63%, with a median of 103.03% recorded in 2022.
- Peak YoY movement for Operating Margin: plummeted -747037bps in 2023, then skyrocketed 3357614bps in 2025.
- A 5-year view of Operating Margin shows it stood at 66.41% in 2021, then crashed by -448bps to 363.74% in 2022, then tumbled by -1601bps to 6187.9% in 2023, then plummeted by -41bps to 8726.26% in 2024, then surged by 385bps to 24849.88% in 2025.
- Per Business Quant, the three most recent readings for SABSW's Operating Margin are 24849.88% (Q4 2025), 29287.09% (Q3 2025), and 15124.81% (Q2 2025).